

In Response

To the Editor:

We would like to thank Juan Camilo Vargas-Gonzalez and colleagues for their interest in our paper and for taking the time to express their concerns regarding relative efficacy and safety of pharmacotherapeutic interventions for diabetic peripheral neuropathy (DPN).

The letter to the editor by Juan-Camilo et al. raised a concern about the ranking probabilities of the interventions in the management of DPN. The ranking in the network is not based on the single effect estimates or a relative effect estimate. The calculation of rank probabilities is straightforward in the Bayesian framework. For every MCMC run, each treatment in the study is ranked based on the relative effect estimates. The proportion of MCMC cycles in which the treatment ranks first gives the probability that it is the best among all competing treatments in the study. Similarly, rank probabilities of being second best, third best, and so on are computed for every treatment. Similarly, Nortryptline was ranked highest among all the interventions in 50% reducing the pain based on MCMC model in the simulation model.

Mir Mahmood Asrar

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, SAS Nagar (Mohali).

Sunita Kumari

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, SAS Nagar (Mohali).

Anil Bhansali

Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Boya Chandrasekhar

Clinical Research Unit, Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, SAS Nagar, India

Dipika Bansal, MD

Clinical Research Unit, Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, SAS Nagar, India
E-mail: dipikabansal079@gmail.com